Skip to main content
Erschienen in: European Radiology 12/2016

24.03.2016 | Urogenital

68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging

verfasst von: Thorsten Derlin, Desiree Weiberg, Christoph von Klot, Hans-Jürgen Wester, Christoph Henkenberens, Tobias L. Ross, Hans Christiansen, Axel S. Merseburger, Frank M. Bengel

Erschienen in: European Radiology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Urinary radiotracer excretion of 68Ga-Labelled prostate-specific membrane antigen (PSMA) ligands may complicate the assessment of the prostate region and differentiation of lymph nodes from ureteral activity. The aim of this study was to assess the value of delayed imaging after forced diuresis.

Materials and methods

Sixty-six patients underwent 68Ga-PSMA I&T PET/CT for evaluation of prostate cancer at 60 min post-injection. In subgroups of patients, this was amended by delayed imaging after 180 min post-injection, preceded by furosemide and oral hydration early, at the time of tracer injection, or delayed, at 100 min post-injection. Urinary tracer activity within the bladder and focal ureteral activity was analyzed.

Results

After forced diuresis, linear and focal visualization of ureters was significantly reduced. After delayed furosemide, mean and peak bladder activity decreased (p < 0.001), and image quality of the prostate region improved on delayed images (p < 0.001). Early furosemide co-injection with tracer resulted in increased mean and peak bladder activity (p < 0.001) and in deteriorated image quality of the prostate region on delayed images (p = 0.008).

Conclusion

Ga-PSMA I&T PET/CT delayed imaging after forced diuresis can improve the assessment of prostate region and pelvic lymph nodes by removing excreted tracer from the lower urinary tract.

Key points

Forced diuresis can improve image quality in 68 Ga-PSMA I&T.
After forced diuresis, linear and focal visualization of ureters was reduced.
Timing of diuresis relative to 68 Ga-PSMA I&T injection is important.
Early furosemide co-injection with tracer resulted in deteriorated image quality on delayed images.
After delayed furosemide, image quality improved on delayed images.
Literatur
1.
Zurück zum Zitat Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495CrossRefPubMed Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495CrossRefPubMed
2.
Zurück zum Zitat Weineisen M, Schottelius M, Simecek J et al (2015) 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 56:1169–1176CrossRefPubMed Weineisen M, Schottelius M, Simecek J et al (2015) 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 56:1169–1176CrossRefPubMed
3.
Zurück zum Zitat Herrmann K, Bluemel C, Weineisen M et al (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56:855–861CrossRefPubMedPubMedCentral Herrmann K, Bluemel C, Weineisen M et al (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56:855–861CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56:668–674CrossRefPubMed Eiber M, Maurer T, Souvatzoglou M et al (2015) Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56:668–674CrossRefPubMed
5.
Zurück zum Zitat Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209CrossRefPubMed Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209CrossRefPubMed
6.
Zurück zum Zitat Cho SY, Gage KL, Mease RC et al (2012) Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 53:1883–1891CrossRefPubMedPubMedCentral Cho SY, Gage KL, Mease RC et al (2012) Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 53:1883–1891CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Benešová M, Schäfer M, Bauder-Wüst U et al (2015) Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med 56:914–920CrossRefPubMed Benešová M, Schäfer M, Bauder-Wüst U et al (2015) Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med 56:914–920CrossRefPubMed
8.
Zurück zum Zitat Chang SS, O'Keefe DS, Bacich DJ et al (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed Chang SS, O'Keefe DS, Bacich DJ et al (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMed
9.
Zurück zum Zitat Weineisen M, Simecek J, Schottelius M et al (2014) Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 4:63CrossRefPubMedPubMedCentral Weineisen M, Simecek J, Schottelius M et al (2014) Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 4:63CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Subhas N, Patel PV, Pannu HK et al (2005) Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 25:1031–1043CrossRefPubMed Subhas N, Patel PV, Pannu HK et al (2005) Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 25:1031–1043CrossRefPubMed
11.
Zurück zum Zitat Koyama K, Okamura T, Kawabe J et al (2003) Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44:353–358PubMed Koyama K, Okamura T, Kawabe J et al (2003) Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J Nucl Med 44:353–358PubMed
12.
Zurück zum Zitat Kamel EM, Jichlinski P, Prior JO et al (2006) Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 47:1803–1807PubMed Kamel EM, Jichlinski P, Prior JO et al (2006) Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med 47:1803–1807PubMed
13.
Zurück zum Zitat Anjos DA, Etchebehere EC, Ramos CD et al (2007) 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 48:764–770CrossRefPubMed Anjos DA, Etchebehere EC, Ramos CD et al (2007) 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 48:764–770CrossRefPubMed
14.
Zurück zum Zitat Nayak B, Dogra PN, Naswa N et al (2013) Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging 40:386–393CrossRefPubMed Nayak B, Dogra PN, Naswa N et al (2013) Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging 40:386–393CrossRefPubMed
15.
Zurück zum Zitat Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41:887–897CrossRefPubMed Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al (2014) Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41:887–897CrossRefPubMed
16.
Zurück zum Zitat Ceci F, Uprimny C, Nilica B et al (2015) 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284–1294CrossRefPubMed Ceci F, Uprimny C, Nilica B et al (2015) 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284–1294CrossRefPubMed
17.
Zurück zum Zitat Martin R, Jüttler S, Müller M, Wester HJ (2014) Cationic eluate pretreatment for automated synthesis of [68Ga]CPCR4.2. Nucl Med Biol 41:84–89CrossRefPubMed Martin R, Jüttler S, Müller M, Wester HJ (2014) Cationic eluate pretreatment for automated synthesis of [68Ga]CPCR4.2. Nucl Med Biol 41:84–89CrossRefPubMed
18.
Zurück zum Zitat Mühlenbruch G, Behrendt FF, Eddahabi MA et al (2008) Which Iodine concentration in chest CT?--a prospective study in 300 patients. Eur Radiol 18:2826–2832CrossRefPubMed Mühlenbruch G, Behrendt FF, Eddahabi MA et al (2008) Which Iodine concentration in chest CT?--a prospective study in 300 patients. Eur Radiol 18:2826–2832CrossRefPubMed
19.
Zurück zum Zitat Dietlein M, Kobe C, Kuhnert G et al (2015) Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol 17:575–584CrossRefPubMedPubMedCentral Dietlein M, Kobe C, Kuhnert G et al (2015) Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol 17:575–584CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol 68:530–534CrossRefPubMed Maurer T, Weirich G, Schottelius M et al (2015) Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol 68:530–534CrossRefPubMed
Metadaten
Titel
68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging
verfasst von
Thorsten Derlin
Desiree Weiberg
Christoph von Klot
Hans-Jürgen Wester
Christoph Henkenberens
Tobias L. Ross
Hans Christiansen
Axel S. Merseburger
Frank M. Bengel
Publikationsdatum
24.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 12/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4308-4

Weitere Artikel der Ausgabe 12/2016

European Radiology 12/2016 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.